| VSE BSI (n=67) | VRE BSI (n=24) | p-value |
---|---|---|---|
Age, years | 48.0±14.0 | 44.9±14.5 | 0.356 |
Male sex | 41 (61.2) | 10 (41.7) | 0.098 |
Underlying hematologic diseases | Â | Â | 0.046 |
  AML | 41 (61.2) | 10 (41.7) | 0.098 |
  ALL | 18 (26.9) | 13 (54.2) | 0.015 |
  Othersa | 8 (11.9) | 1 (4.2) | 0.436 |
Treatment for underlying diseases | Â | Â | 0.861 |
  Chemotherapy | 56 (83.6) | 20 (83.3) | >0.999 |
  Allogeneic SCT | 9 (13.4) | 4 (16.7) | 0.738 |
  Autologous SCT | 2 (3.0) | 0 (0) | >0.999 |
Enterococcal species | Â | Â | <0.001 |
  E. faecium | 44 (65.7) | 22 (91.7) | 0.016 |
  E. faecalis | 23 (34.3) | 0 (0.0) | <0.001 |
  E. gallinarum | 0 (0.0) | 2 (8.3) | 0.067 |
SAPS II at the onset of BSI | 39 (28–95) | 41 (31–74) | 0.336 |
Charlson’s comorbidity index | 2 (0–4) | 2 (0–4) | 0.644 |
ICU care | 16 (23.9) | 7 (29.2) | 0.609 |
Septic shock | 8 (11.9) | 2 (8.3) | >0.999 |
Length of hospitalization, day | 22 (13–44) | 26 (17–77) | 0.025 |
Duration of neutropenia before BSI, day | 14 (0–156) | 15 (6–27) | 0.908 |
Severity of neutropenia | Â | Â | 0.112 |
  ANC <500/mm3 | 2 (3.0) | 3 (12.5) |  |
  ANC <100/mm3 | 65 (97.0) | 21 (87.5) |  |
Administration of adequate antibiotics | Â | Â | 0.002 |
  ≤48 hours after febrile episode | 50 (75.8) | 10 (41.7) |  |
  >48 hours after febrile episode | 16 (24.2) | 14 (58.3) |  |